JP2017511327A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511327A5
JP2017511327A5 JP2016560336A JP2016560336A JP2017511327A5 JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5 JP 2016560336 A JP2016560336 A JP 2016560336A JP 2016560336 A JP2016560336 A JP 2016560336A JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5
Authority
JP
Japan
Prior art keywords
composition
subject
related antigen
administration
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560336A
Other languages
English (en)
Japanese (ja)
Other versions
JP6655549B2 (ja
JP2017511327A (ja
Filing date
Publication date
Priority claimed from GBGB1405921.6A external-priority patent/GB201405921D0/en
Application filed filed Critical
Publication of JP2017511327A publication Critical patent/JP2017511327A/ja
Publication of JP2017511327A5 publication Critical patent/JP2017511327A5/ja
Application granted granted Critical
Publication of JP6655549B2 publication Critical patent/JP6655549B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560336A 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法 Expired - Fee Related JP6655549B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511327A JP2017511327A (ja) 2017-04-20
JP2017511327A5 true JP2017511327A5 (https=) 2018-05-17
JP6655549B2 JP6655549B2 (ja) 2020-02-26

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Country Status (18)

Country Link
US (3) US10688168B2 (https=)
EP (2) EP3125929B8 (https=)
JP (2) JP6645982B2 (https=)
KR (2) KR20160132115A (https=)
CN (2) CN106456739A (https=)
AR (1) AR099960A1 (https=)
AU (1) AU2015239025B2 (https=)
BE (1) BE1022355B1 (https=)
BR (2) BR112016022463A2 (https=)
CA (2) CA2943007C (https=)
EA (1) EA037405B1 (https=)
ES (2) ES2853773T3 (https=)
GB (1) GB201405921D0 (https=)
IL (1) IL247493B (https=)
MX (3) MX2016012982A (https=)
SG (1) SG11201607086QA (https=)
WO (2) WO2015150567A1 (https=)
ZA (1) ZA201605955B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
KR20230013237A (ko) 2020-03-09 2023-01-26 다이나박스 테크놀로지 코퍼레이션 Tlr9 효능제를 포함하는 대상포진 백신
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
EP2426141B1 (en) * 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
HRP20161606T1 (hr) * 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
MX2011000982A (es) * 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
PT2315773T (pt) * 2008-07-25 2016-11-23 Glaxosmithkline Biologicals Sa Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
HUE037121T2 (hu) * 2008-07-25 2018-08-28 Glaxosmithkline Biologicals Sa Új készítmények és eljárások
SI2528621T1 (sl) * 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
PL2651436T3 (pl) * 2010-12-14 2016-10-31 Kompozycja antygenów mykobakteryjnych
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2017511327A5 (https=)
Akache et al. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice
JP2017511324A5 (https=)
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2008539187A5 (https=)
JP2018500322A5 (https=)
BRPI0412444B1 (pt) fração de quil a com baixa toxidez e seu uso
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
JP2020528911A5 (https=)
Lowell et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
TWI630915B (zh) 無細胞百日咳疫苗
JP2015500827A5 (https=)
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
EP3125930B1 (en) Novel methods for inducing an immune response
JP2015524802A5 (https=)
RU2015100889A (ru) Вакцины для менингококка серогруппы х
JP2021514387A5 (https=)
CN110621339A (zh) 疫苗接种
JP2015529677A5 (https=)
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
JP2018532782A5 (https=)
Baz et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
Faingezicht et al. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine
US11771757B2 (en) Compositions and methods of manufacturing trivalent filovirus vaccines